Canonical nuclear factor κB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 6010-6018

  Romagnoli, Mathilde ^a,b   Desplanques, Grégoire ^a,b   Maïga, Sophie ^a,d   Legouill, Steven ^a,c   Dreano, Michel ^e   Bataille, Régis ^a,b,d   Barillé Nion, Sophie ^a,b,f  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e Serono International SA   (Switzerland)

^f UMR 601   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AS 602868; CASPASE 3; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PROTEIN BAX; RECOMBINANT INTERLEUKIN 6; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MONONUCLEAR CELL; MOUSE; MYELOMA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MICE; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PYRIMIDINES; RECEPTORS, IMMUNOLOGIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 35948980027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0140     Document Type: Article

References (35)

1. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
2. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18:2195-224.
3. Yemelyanov A, Gasparian A, Lindholm P, et al. Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006;25:387-98.
4. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-κB in hematologic malignancies. Cell Death Differ 2006;13:748-58.
5. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
6. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
7. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
8. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005;105:804-11.
9. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11: 28-40.
10. Braun T, Carvalho G, Coquelle A, et al. NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006;107:1156-65.
11. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-{κ}B pathway. Blood 2007;109:703-10.
12. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br J Haematol 2001;115:279-86.
13. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutict arget in multiple myeloma. J Biol Chem 2002;277:16639-47.
14. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171:3863-71.
15. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996;87:1104-12.
16. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
17. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999;13:1817-24.
18. Spencer A, Yeh SL, Koutrevelis K, Baulch-Brown C. TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio. Blood 2002;100:3049-50.
19. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006;108:1346-52.
20. Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemicc ells. Oncogene 2003; 22:8187-94.
21. Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006;91: 1234-40.
22. Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999;163:5723-8.
23. Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999;94:701-12.
24. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20: 4519-27.
25. Jourdan M, Moreaux J, Hose D, et al. Inhibition of multiple myeloma cells growth by AS602868, a pharmacological inhibitor of IKK2 [abstract 3472]. Blood 2006;108.
26. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-9.
27. Mitsiades N, Mitsiades C, Anderson KC, Treon SP. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is modulated by FLICE-inhibitory protein (FLIP) and procaspase-8 in multiple myeloma cells. Blood 2002;200:3049-51.
28. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997;7:821-30.
29. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat Cell Biol 2001;3: 409-16.
30. Fandy TE, Ross DD, Gore SD, Srivastava RK. Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIP(L). Cancer Chemother Pharmacol 2007; 60:313-9.
31. Roue G, Perez-Galan P, Lopez-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007;178:1923-30.
32. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (Bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-8.
33. Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S. Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 2004;103:2761-70.
34. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-62.
35. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99: 4079-86.